復星醫藥AH齊漲 傳中國加快引進“復必泰” 將作為加強針免費施打
格隆匯7月15日丨復星醫藥(2196.HK)盤初大漲漲近7%,報61.3港元;復星醫藥(600196.SH)漲逾5%,報68.17元。據財新,復星醫藥在股東大會上回復投資人問詢時表示,國家藥監局對mRNA新冠疫苗“復必泰”的審定工作已經基本完成,專家評審已經通過了,目前正在加緊進行行政審批階段。復星醫藥已與BioNTech提前啟動生產準備工作,復必泰疫苗一旦獲批,就能第一時間供應到國內;知情人士稱,未來,復必泰在國內很可能會作為加強針使用,免費接種。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.